Dermatology

>

Latest News

Dermavant: FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Adults, Children with Atopic Dermatitis / image credit eczema ©InfiniteStudio/stock.adobe.com
Dermavant: FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Adults, Children with Atopic Dermatitis

April 29th 2024

The FDA PDUFA date for taparinof cream 1% will be during the 4th quarter, Dermavant said, with approval based on ADORING phase 3 clinical trial data.

Tapinarof Cream 1.0% Effective for Atopic Dermatitis: Daily Dose / image credit: ©New Africa/AdobeStock
Tapinarof Cream 1.0% Effective for Atopic Dermatitis: Daily Dose

March 25th 2024

Tapinarof Cream 1% Effective for Atopic Dermatitis in Person with Skin of Color  / image credit diversity: ©marina/stock.adobe.com
Tapinarof Cream 1.0% Effective for Atopic Dermatitis in Persons with Skin of Color: ADORING Phase 3 Program

March 11th 2024

Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study / image credit ©Brian Jackson/stock.adobe.com
Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study

February 21st 2024

Tezepelumab Treatment Leads to Sustained Reductions in CSU Disease Activity, Inflammatory Markers / image credit hives; ©chomplearn/stock.adobe.com
Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers

February 21st 2024

Latest CME Events & Activities

"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation

View More

PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa

View More

Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care

View More

Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

October 16, 2024

Register Now!

Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)

View More

Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Community Practice Connections™: 20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

More News

© 2024 MJH Life Sciences

All rights reserved.